Sogen Data · Datasets · 数据专题
胶质瘤复发轴数据集锦
单细胞 · 空转 · bulk 转录组
本专题承自 Sogen Data 数据整理体系,逐条人工复核,附研究设计、样本量、平台与 GEO/PubMed 直达链接。
人源单细胞
Human · Single-cell
-
01 GSE274546 对121例胶质母细胞瘤(GBM)单核进行RNA测序,分析其转录特征,区分原发性与复发性样本,涵盖多个研究队列。
设计对121例胶质母细胞瘤(GBM)单核进行RNA测序,分析其转录特征,区分原发性与复发性样本,涵盖多个研究队列。
摘要To comprehensively define the cellular heterogeneity of glioblastoma (GBM), the GBM CARE (Cellular Analysis of Resistance and Evolution) consortium set out to profile 121 GBMs with extensive clinical annotation, by single-nucleus RNA-sequencing and bulk tumor DNA sequencing. The resulting dataset enabled us to characterize GBM heterogeneity at three levels. First, GBMs are classified by their cellular composition, encompassing malignant, immune, neuronal and glial cell types. Second, within each cell type, and particularly among the malignant cells, we describe the diversity of cellular states and their pathway-based functional activities. Third, after controlling for the frequencies of cellular states, we find that the remaining variation between GBMs highlights three baseline gene expression programs which we labeled Neuronal, Glial, and Extracellular Matrix. These three layers of heterogeneity are inter-related and partially associated with specific genetic aberrations, thereby defining three stereotypic ecosystems in GBM. This work provides an unparalleled view of the multi-layered transcriptional architecture of GBM.
-
02 GSE228497 对原发性胶质母细胞瘤(primary glioma)和复发性胶质母细胞瘤(recurrent glioma)组织进行单核 RNA 测序,定义三种基于细胞类型共存和转录状态的‘组织状态’,并利用空间转录组学验证其空间共存性,比较不同组织状态的基因表达特征。
设计对原发性胶质母细胞瘤(primary glioma)和复发性胶质母细胞瘤(recurrent glioma)组织进行单核 RNA 测序,定义三种基于细胞类型共存和转录状态的‘组织状态’,并利用空间转录组学验证其空间共存性,比较不同组织状态的基因表达特征。
摘要Glioblastoma is an aggressive diffusely infiltrating neoplasm that spreads beyond surgical resection margins, where it intermingles with non-neoplastic brain cells. This complex microenvironment harbouring infiltrating glioma and non-neoplastic brain cells is the origin of tumor recurrence. Thus, understanding the cellular and molecular features of the glioma microenvironment is therapeutically and prognostically important. Here, we used single-nucleus RNA sequencing (snRNAseq) of primary and recurrent glioma to define three compositional ‘tissue-states’ rooted in cohabitation of cell-types and transcriptional states. These comprise a state featuring A) minimally infiltrated-brain, B) reactive inflamed infiltrated tissue, and C) cellular tumor. Spatial transcriptomics confirmed that the cell-types and transcriptomics states which compositionally cohabitate indeed do colocalize in space. Tissue states are clinically significant because they correlate with radiographic, histopathologic, and prognostic features. We found that in addition to enrichment of tissue state B signature, enrichment of both neoplastic and non-neoplastic cell-type gene signatures in tissue state B correlated with decreased survival. Importantly, we found that our compositionally defined tissue states are enriched in distinct metabolic pathways. One such pathway is fatty acid biosynthesis, which was enriched in tissue state B – a state enriched in recurrent glioblastoma and composed of astrocyte-like/mesenchymal glioma cells, reactive astrocytes resembling those seen in neurodegeneration, and monocyte-like myeloid cells. We discovered that targeting fatty acid synthesis was sufficient to deplete the transcriptional signature of tissue state B. Our findings define a novel compositional approach to the glioma infiltrated tissue which allows us to discover prognostic and targetable features, paving the way to new mechanistic and therapeutic discoveries.
-
03 GSE326221 对75个时间分离的IDH突变胶质瘤样本进行单核RNA测序,分析恶性细胞状态的转录特征、染色质可及性及整体DNA/RNA测序数据,比较不同恶性细胞状态的基因表达和染色质可及性差异。
设计对75个时间分离的IDH突变胶质瘤样本进行单核RNA测序,分析恶性细胞状态的转录特征、染色质可及性及整体DNA/RNA测序数据,比较不同恶性细胞状态的基因表达和染色质可及性差异。
摘要Isocitrate dehydrogenase (IDH)-mutant gliomas are malignant brain tumors that typically arise in early- to mid-adulthood and nearly always recur following treatment. However, the genetic and cellular state changes that drive IDH-mutant glioma progression under treatment remain incompletely understood. Here, we integrated single-nucleus transcriptomic profiles, chromatin accessibility profiles and bulk DNA/RNA sequencing from 75 temporally separated gliomas across 35 patients comprising both the oligodendroglioma and astrocytoma IDH-mutant glioma tumor types. We show that malignant cell states transcriptionally resemble stages of normal glial-neuronal lineage development or a reactive mesenchymal-like state, mirroring states previously described in IDH-wildtype glioblastoma. Malignant cell states displayed distinct chromatin accessibility profiles that were comparable between both IDH-mutant glioma types. The abundance of less differentiated malignant cells increased with grade and with genetic alterations such as PDGFRA amplification. Longitudinal analysis highlighted two major malignant cell state transition patterns. First, reduced lineage differentiation and increased proliferative malignant cells at recurrence were pronounced in gliomas that acquired recurrence-associated genetic events, including treatment-associated hypermutation, increased copy number changes, and cell cycle alterations. Second, increased mesenchymal-like state abundance occurred independently of acquired genetic alterations and instead coincided with heightened macrophage expression. Overall, our findings provide an integrative model that traces the cell-intrinsic and extrinsic factors that shape cellular states during IDH-mutant glioma disease progression.
-
04 GSE289864 将 glioblastoma (GBM) 患者按新诊断、复发未接受免疫治疗、复发接受新辅助抗 PD-1 治疗分为三组,共 46 个 GSM 样本。从各组 GBM 肿瘤组织中分离 CD45+ 细胞,进行单细胞 RNA 测序和单细胞 TCR 测序,检测肿瘤浸润免疫细胞转录组特征,比较不同治疗状态下的 CD45+ 细胞转录组差异。
设计将 glioblastoma (GBM) 患者按新诊断、复发未接受免疫治疗、复发接受新辅助抗 PD-1 治疗分为三组,共 46 个 GSM 样本。从各组 GBM 肿瘤组织中分离 CD45+ 细胞,进行单细胞 RNA 测序和单细胞 TCR 测序,检测肿瘤浸润免疫细胞转录组特征,比较不同治疗状态下的 CD45+ 细胞转录组差异。
摘要Glioblastoma (GBM) is the most aggressive primary brain cancer in adults and remains incurable. We used multi-omics and flow cytometry methods to investigate the role of mucosal-associated invariant T (MAIT) cells in GBM. In bulk RNA sequencing data analysis of GBM tissues, MAIT cell gene signature significantly correlated with poor patient survival. A scRNA-seq of CD45+ cells from 23 GBM tissue samples showed a diverse immune population in the GBM tumor microenvironment. Of the 23 GBM tissue samples analyzed, 15 (65.2%) were positive for MAIT cells. MAIT cells clustered with cell populations expressing a high level of transcription factor gene RORC, suggesting the enrichment of MAIT17 subset. The MAIT cell signature significantly correlated with the activity of tumor-associated neutrophils (TANs) and myeloid-derived suppressor cells (MDSCs). Multiple immune suppressive genes known to be used by TANs/MDSCs were upregulated in MAIT-positive tumors. Spatial imaging analysis of GBM tissues showed that all specimens were positive for both MAIT cells and TANs and localized enrichment of TANs. These findings highlight the MAIT-TAN/MDSC axis as a novel therapeutic target to modulate GBM’s immunosuppressive tumor microenvironment.
-
05 GSE154795 对新发和复发胶质母细胞瘤患者的肿瘤浸润淋巴细胞和巨噬细胞进行单细胞RNA测序,比较接受或未接受新辅助PD-1阻断治疗的样本中免疫细胞的转录特征。
设计对新发和复发胶质母细胞瘤患者的肿瘤浸润淋巴细胞和巨噬细胞进行单细胞RNA测序,比较接受或未接受新辅助PD-1阻断治疗的样本中免疫细胞的转录特征。
摘要The differentiation and effector function of tumor infiltrating lymphocytes and macrophages in the tumor microenvironment is critical for productive anti-tumor immune responses, although direct evidence for this remains poorly characterized in brain cancer patients. Using mass cytometry, single-cell RNA sequencing, and quantitative multiplex immunofluorescence, we comprehensively characterized the phenotype and single-cell transcriptome of myeloid cells and T lymphocytes that infiltrated malignant gliomas, and identified how such populations changed following neoadjuvant PD-1 checkpoint blockade in recurrent glioblastoma patients. Cells of the myelo-monocytic lineage represented approximately three quarters of the immune cell infiltrate, with T lymphocytes representing the next major immune cell subset by density and percentage, but following neoadjuvant PD-1 antibody blockade, the ratio of myeloid cells to T cells significantly decreased. We then used single-cell RNA sequencing to comprehensively define the transcriptional profiles of lymphoid and myeloid populations in these tumors. Recurrent GBM patients treated with neoadjuvant PD-1 checkpoint inhibition possessed a greater fraction of CD8+ T cells with an effector T cell transcriptional program. The increased effector T cell populations were associated with the distinct upregulation of the chemokines, CXCL9 and CXCL10 by an interferon-responsive macrophage cluster. Importantly, we also identified that neoadjuvant PD-1 blockade was associated with significantly increased cellular interactions specifically between CD8+ T cells and tumor associated macrophages within the tumor microenvironment. Together, these findings suggest that effector T cell infiltration and differentiation are increased with neoadjuvant PD-1 blockade but impeded by adaptive resistance and immunosuppression from tumor associated macrophages. Future therapeutic strategies to target this dominant immunosuppressive myeloid cell population may be needed to achieve true, therapeutic interventions in this patient population.
-
06 GSE200984 对原发性与复发性胶质母细胞瘤组织进行单核RNA测序和空间转录组学分析,比较其组织状态组成差异。
设计对原发性与复发性胶质母细胞瘤组织进行单核RNA测序和空间转录组学分析,比较其组织状态组成差异。
摘要Glioblastoma is an aggressive diffusely infiltrating neoplasm that spreads beyond surgical resection margins, where it intermingles with non-neoplastic brain cells. This complex microenvironment harbouring infiltrating glioma and non-neoplastic brain cells is the origin of tumor recurrence. Thus, understanding the cellular and molecular features of the glioma microenvironment is therapeutically and prognostically important. Here, we used single-nucleus RNA sequencing (snRNAseq) of primary and recurrent glioma to define three compositional ‘tissue-states’ rooted in cohabitation of cell-types and transcriptional states. These comprise a state featuring A) minimally infiltrated-brain, B) reactive inflamed infiltrated tissue, and C) cellular tumor. Spatial transcriptomics confirmed that the cell-types and transcriptomics states which compositionally cohabitate indeed do colocalize in space. Tissue states are clinically significant because they correlate with radiographic, histopathologic, and prognostic features. We found that in addition to enrichment of tissue state B signature, enrichment of both neoplastic and non-neoplastic cell-type gene signatures in tissue state B correlated with decreased survival. Importantly, we found that our compositionally defined tissue states are enriched in distinct metabolic pathways. One such pathway is fatty acid biosynthesis, which was enriched in tissue state B – a state enriched in recurrent glioblastoma and composed of astrocyte-like/mesenchymal glioma cells, reactive astrocytes resembling those seen in neurodegeneration, and monocyte-like myeloid cells. We discovered that targeting fatty acid synthesis was sufficient to deplete the transcriptional signature of tissue state B. Our findings define a novel compositional approach to the glioma infiltrated tissue which allows us to discover prognostic and targetable features, paving the way to new mechanistic and therapeutic discoveries.
-
07 GSE222520 将IDH突变型原发(IMP,n=4)、IDH突变型复发(IMR,n=6)、IDH野生型原发(IWP,n=4)、IDH野生型复发(IWR,n=4)胶质瘤患者及准正常非胶质瘤脑组织(NGB,n=3)的CD45+白细胞通过流式细胞术分选,进行单细胞RNA测序,比较不同IDH状态及原发与复发肿瘤的免疫细胞转录特征差异。
设计将IDH突变型原发(IMP,n=4)、IDH突变型复发(IMR,n=6)、IDH野生型原发(IWP,n=4)、IDH野生型复发(IWR,n=4)胶质瘤患者及准正常非胶质瘤脑组织(NGB,n=3)的CD45+白细胞通过流式细胞术分选,进行单细胞RNA测序,比较不同IDH状态及原发与复发肿瘤的免疫细胞转录特征差异。
摘要The brain tumor immune microenvironment (TIME) continuously evolves during glioma progression, but only a limited view of a highly complex glioma associated immune contexture across isocitrate dehydrogenase mutation (IDH) classified gliomas is known. Herein, we present an unprecedentedly comprehensive view of myeloid and lymphoid cell type diversity with our single cell RNA sequencing interrogation.
-
08 GSE236082 对IDH突变型原发(IMP; n=4)和复发(IMR; n=4)胶质瘤患者、IDH野生型原发(IWP; n=3)和复发(IWR; n=4)患者的脑肿瘤组织以及准正常非胶质瘤脑组织(NGB; n=2)进行流式细胞术分离CD45+白细胞,提取总RNA后开展单细胞RNA测序,比较不同IDH状态和复发/原发状态下的T细胞基因表达特征。
设计对IDH突变型原发(IMP; n=4)和复发(IMR; n=4)胶质瘤患者、IDH野生型原发(IWP; n=3)和复发(IWR; n=4)患者的脑肿瘤组织以及准正常非胶质瘤脑组织(NGB; n=2)进行流式细胞术分离CD45+白细胞,提取总RNA后开展单细胞RNA测序,比较不同IDH状态和复发/原发状态下的T细胞基因表达特征。
摘要The brain tumor immune microenvironment (TIME) continuously evolves during glioma progression, but only a limited view of a highly complex glioma associated immune contexture across isocitrate dehydrogenase mutation (IDH) classified gliomas is known. Herein, we present an unprecedentedly comprehensive view of T cells from brain TIME at single cell resolution, which served as part of our pan-cancer T cell atlas analysis.
-
09 GSE339010 对7名复发性胶质母细胞瘤患者的肿瘤周围脑组织进行配对分析,分别采集声波处理后45分钟的sonicated与相邻non-sonicated样本,通过单细胞RNA测序比较两种处理状态下的转录组差异。
设计对7名复发性胶质母细胞瘤患者的肿瘤周围脑组织进行配对分析,分别采集声波处理后45分钟的sonicated与相邻non-sonicated样本,通过单细胞RNA测序比较两种处理状态下的转录组差异。
摘要The blood–brain barrier (BBB) restricts entry of therapeutics and shapes immune surveillance in the central nervous system, while microglia maintain barrier integrity and coordinate repair. Low-intensity pulsed ultrasound with intravenously administered microbubbles (LIPU/MB) transiently opens the BBB in patients, with restoration mostly occurring within about an hour; however, how microglia respond to LIPU/MB during this acute repair window in the human brain remains unknown. We report on intraoperative LIPU/MB studies where the peritumoral brain of glioblastoma patients was biopsied 45 minutes after sonication and analyzed, as part of phase I/II clinical trials (NCT04528680). We integrated single-cell RNA-seq, single-cell ATAC-seq, spatial transcriptomics, and multiplex immunofluorescence. We observe that LIPU/MB modulates perivascular microglia by promoting extension of processes toward the endothelium, inducing pro-inflammatory and chemoattractant transcriptional programs, and remodeling of endothelial–myeloid ligand–receptor communication. We find that microglial reprogramming is accompanied by coordinated changes in chromatin accessibility and heightened activity of the AP-1 transcription factor complex. These results reveal that LIPU/MB-based BBB opening in humans does not merely permit drug passage but reprograms resident myeloid cells to engage the vasculature and amplify innate and adaptive immune pathways, providing a mechanistic basis to leverage immune activation by LIPU/MB with immunotherapies for brain tumors. These findings also warrant consideration in the context of the pathophysiology and therapeutics of CNS diseases where there is acute BBB disruption, or where LIPU/MB is under investigation.
-
10 GSE103224 对8名人类高分级胶质瘤组织细胞进行单细胞RNA测序,分析其细胞组成、线系身份及微环境特征。研究对象包括胶质母细胞瘤(WHO IV级)和间变性星形细胞瘤(WHO III级)样本,部分样本为复发性肿瘤。根据IDH1突变状态(R132H或野生型)和EGFR扩增情况(扩增或未扩增)进行分组,比较不同分子亚型下肿瘤细胞与髓系细胞的基因表达差异。
设计对8名人类高分级胶质瘤组织细胞进行单细胞RNA测序,分析其细胞组成、线系身份及微环境特征。研究对象包括胶质母细胞瘤(WHO IV级)和间变性星形细胞瘤(WHO III级)样本,部分样本为复发性肿瘤。根据IDH1突变状态(R132H或野生型)和EGFR扩增情况(扩增或未扩增)进行分组,比较不同分子亚型下肿瘤细胞与髓系细胞的基因表达差异。
摘要Despite extensive molecular characterization, we lack a comprehensive picture of lineage identity, differentiation, and microenvironmental composition in high-grade gliomas (HGGs). We sampled the cellular milieu of HGGs with massively-parallel single-cell RNA-Seq. While HGG cells can resemble glia or even immature neurons and form branched lineage structures, mesenchymal transformation results in unstructured populations. Glioma cells in a subset of mesenchymal tumors lose their neural lineage identity, express inflammatory genes, and co-exist with marked myeloid infiltration, implying a molecular interaction between glioma and immune cells. Finally, we found that myeloid cells can resemble microglia, macrophages, or a hybrid state, and enrichment of these cells is predictive of poor survival.
-
11 GSE331374 对人类胶质母细胞瘤复发样本进行空间转录组(Visium)与单核RNA测序,比较原发肿瘤与复发肿瘤的转录特征,同时分析不同治疗条件下的基因表达变化。研究对象为BRAF V600E突变的脑/胶质母细胞瘤组织,分组包括未处理(Naive)、BRAF/MEK抑制剂(BRAFi/MEKi)和替莫唑胺(Temozolomide)处理组,每组采用Visium和scRNA-seq两种检测方式,按总单位数与组数估计各组样本量。
设计对人类胶质母细胞瘤复发样本进行空间转录组(Visium)与单核RNA测序,比较原发肿瘤与复发肿瘤的转录特征,同时分析不同治疗条件下的基因表达变化。研究对象为BRAF V600E突变的脑/胶质母细胞瘤组织,分组包括未处理(Naive)、BRAF/MEK抑制剂(BRAFi/MEKi)和替莫唑胺(Temozolomide)处理组,每组采用Visium和scRNA-seq两种检测方式,按总单位数与组数估计各组样本量。
摘要Glioblastoma (GBM) remains a formidable challenge in neuro-oncology, with immune checkpoint blockade (ICB) only showing efficacy in some patients, while the mechanisms governing therapeutic responsiveness are poorly defined. Although MAPK/ERK signaling correlates with survival following ICB, its causal role and mechanisms underlying tumor immunogenicity remain unclear. Here, we perform in vivo kinome-wide CRISPR/Cas9 screens in murine gliomas where we identify RAF-MEK-ERK axis as the strongest modulators of glioma susceptibility to anti-programmed cell death protein 1 (anti-PD-1) therapy and CD8+ T cell recognition. Experimentally-induced ERK phosphorylation (p-ERK) enhances survival after anti-PD-1 and anti-CLTA4, leading to durable antitumor immunity upon rechallenge. Additionally, glioma cell p-ERK promotes increased interferon responses and T cell infiltration. Notably, BRAF/MEK inhibition disrupts interferon programs and tumor-microglia interactions in BRAFV600E ex vivo in human GBM/brain slice cultures. Our findings elucidate that tumor-intrinsic MAPK/ERK promotes immunotherapy response, interferon responses, T cell tumor infiltration, and GBM cell-microglia interactions.
-
12 GSE167960 对6例人类复发性胶质瘤样本进行单细胞RNA测序,每例样本约3000个细胞被分选并分析,基于WHO分级将样本分为IV级(1例)和III级(5例)两组,采用微孔阵列平台分离单细胞,使用Illumina Hiseq 4000测序,比较不同WHO分级样本的转录组差异。
设计对6例人类复发性胶质瘤样本进行单细胞RNA测序,每例样本约3000个细胞被分选并分析,基于WHO分级将样本分为IV级(1例)和III级(5例)两组,采用微孔阵列平台分离单细胞,使用Illumina Hiseq 4000测序,比较不同WHO分级样本的转录组差异。
摘要Six freshly resected recurrent glioma samples were obatined to analyze the diversity of expression states of human gliomas. About 3000 cells from each sample were profiled.
-
13 GSE214966 对成人胶质母细胞瘤患者样本(P007, P011, P012, P013)的单细胞悬液进行荧光激活细胞分选(FACS),分选活化 CD45+ 免疫细胞与 CD45- 胶质母细胞瘤细胞,采用单细胞 RNA 测序技术检测转录组特征,比较两类细胞的基因表达差异。
设计对成人胶质母细胞瘤患者样本(P007, P011, P012, P013)的单细胞悬液进行荧光激活细胞分选(FACS),分选活化 CD45+ 免疫细胞与 CD45- 胶质母细胞瘤细胞,采用单细胞 RNA 测序技术检测转录组特征,比较两类细胞的基因表达差异。
摘要Glioblastoma is the most common type of malignant brain tumor among adults. We used single-cell RNA sequencing (scRNA-seq) to analyze the diversity of glioblastoma cells.
人源空转
Human · Spatial
-
01 GSE254145 对7名患者匹配的原发性与复发性胶质母细胞瘤(GBM)样本进行空间转录组分析,分别检测CD64+(FCGR1A)髓样细胞和GFAP+肿瘤细胞的基因表达,比较两组间差异基因与蛋白的表达特征,分析复发时间与基因表达的相关性。
设计对7名患者匹配的原发性与复发性胶质母细胞瘤(GBM)样本进行空间转录组分析,分别检测CD64+(FCGR1A)髓样细胞和GFAP+肿瘤细胞的基因表达,比较两组间差异基因与蛋白的表达特征,分析复发时间与基因表达的相关性。
摘要Introduction: Glioblastoma (GBM) is a lethal brain tumor without effective treatment options. Here, we sought to characterize longitudinal tumor immune microenvironment (iTME) changes in order to find potential actionable targets to prevent GBM-induced immune evasion mechanisms. This study included 15 patient-matched treatment-naïve (primary, pGBM, WHO grade 4) and recurrent (rGBM) IDH1 wild type tumors. Methods:Extracted RNA and proteins from fresh frozen tumor samples from matched pGBM and rGBM were profiled via transcriptomics and proteomics, respectively. Paired formalin-fixed paraffin-embedded tumor samples were processed for spatial transcriptomics analysis.Results: Differentially expressed genes and proteins between pGBM and rGBM were involved in pathways responsible for synapse development and myelination which have been shown to play a role in GBM recurrence. By categorizing patients into short and long time-to-relapse (STTR vs LTTR), and by correlating TTR with gene expression, we detected genes positively or negatively associated with tumor relapse. Expression of FCG receptor and complement system genes such as FCGR1A (CD64), FCGR3A (CD16a) and the complement C3 were negatively correlated with STTR, whereas high expression of DNMT1/3A, and SMARCA4, involved in DNA methylation, were positively correlated with LTTR. Spatial transcriptomic analysis of the tumor cells compartment defined by GFAP expression showed enrichment in the proportion of oligodendrocytes in recurrent tumors in rGBM, whereas CD64-positive myeloid cell compartment showed a switch of quiescent to activated microglia, appearance of B cells and a reduction in macrophage proportion in recurrent tumors with STTR. Conclusion: Our results uncover a role of CD64-expressing myeloid cells, mostly activated microglia, in GBM recurrence and suggest that interfering with these cells may represent a new therapeutic option for preventing GBM relapse.
-
02 GSE194329 对需手术切除的11例人类患者来源的弥漫性中线胶质瘤(DMG)和胶质母细胞瘤(GBM)组织样本(含二级GBM及IDH野生型GBM)进行短读空间转录组测序,采集肿瘤周围组织样本,使用10x Visium平台对组织切片实施固定、渗透处理及荧光标记cDNA捕获,比较不同肿瘤亚型的空间基因表达特征。
设计对需手术切除的11例人类患者来源的弥漫性中线胶质瘤(DMG)和胶质母细胞瘤(GBM)组织样本(含二级GBM及IDH野生型GBM)进行短读空间转录组测序,采集肿瘤周围组织样本,使用10x Visium平台对组织切片实施固定、渗透处理及荧光标记cDNA捕获,比较不同肿瘤亚型的空间基因表达特征。
摘要We collected five DMG, five GBM (including two secondary GBM), and one peritumor samples from eleven patients requiring surgical resection. To establish an atlas for spatially-resolved gene expression, we performed short-read spatial transcriptomic sequencing on the tissue sections using the 10x Visium platform.
-
03 GSE339006 对5名复发性胶质母细胞瘤患者的肿瘤周围脑组织进行配对分析,分别接受低强度脉冲超声波联合微泡(LIPU/MB)处理与未处理,采用Xenium空间转录组学、单细胞RNA测序、单细胞ATAC测序及多重免疫荧光技术检测,比较处理组与对照组的空间转录组变化。
设计对5名复发性胶质母细胞瘤患者的肿瘤周围脑组织进行配对分析,分别接受低强度脉冲超声波联合微泡(LIPU/MB)处理与未处理,采用Xenium空间转录组学、单细胞RNA测序、单细胞ATAC测序及多重免疫荧光技术检测,比较处理组与对照组的空间转录组变化。
摘要The blood–brain barrier (BBB) restricts entry of therapeutics and shapes immune surveillance in the central nervous system, while microglia maintain barrier integrity and coordinate repair. Low-intensity pulsed ultrasound with intravenously administered microbubbles (LIPU/MB) transiently opens the BBB in patients, with restoration mostly occurring within about an hour; however, how microglia respond to LIPU/MB during this acute repair window in the human brain remains unknown. We report on intraoperative LIPU/MB studies where the peritumoral brain of glioblastoma patients was biopsied 45 minutes after sonication and analyzed, as part of phase I/II clinical trials (NCT04528680). We integrated single-cell RNA-seq, single-cell ATAC-seq, spatial transcriptomics, and multiplex immunofluorescence. We observe that LIPU/MB modulates perivascular microglia by promoting extension of processes toward the endothelium, inducing pro-inflammatory and chemoattractant transcriptional programs, and remodeling of endothelial–myeloid ligand–receptor communication. We find that microglial reprogramming is accompanied by coordinated changes in chromatin accessibility and heightened activity of the AP-1 transcription factor complex. These results reveal that LIPU/MB-based BBB opening in humans does not merely permit drug passage but reprograms resident myeloid cells to engage the vasculature and amplify innate and adaptive immune pathways, providing a mechanistic basis to leverage immune activation by LIPU/MB with immunotherapies for brain tumors. These findings also warrant consideration in the context of the pathophysiology and therapeutics of CNS diseases where there is acute BBB disruption, or where LIPU/MB is under investigation.
人源bulk 转录组
Human · Bulk RNA-seq
-
01 GSE13041 对267例胶质母细胞瘤(glioblastoma)样本进行基因表达分析,涵盖初次诊断与复发性肿瘤,采集生存时间、年龄、性别等临床信息,通过Kaplan-Meier曲线和Cox比例风险分析比较不同基因表达亚型(如ProNeural)与年龄对生存时间的影响。
设计对267例胶质母细胞瘤(glioblastoma)样本进行基因表达分析,涵盖初次诊断与复发性肿瘤,采集生存时间、年龄、性别等临床信息,通过Kaplan-Meier曲线和Cox比例风险分析比较不同基因表达亚型(如ProNeural)与年龄对生存时间的影响。
摘要Background: Glioblastomas are the most common primary brain tumour in adults. While the prognosis for patients is poor, gene expression profiling has detected signatures that can sub-classify GBMs relative to histopathology and clinical variables. One category of GBM defined by a gene expression signature is termed ProNeural (PN), and has substantially longer patient survival relative to other gene expression-based subtypes of GBMs. Age of onset is a major predictor of the length of patient survival where younger patients survive longer than older patients. The reason for this survival advantage has not been clear. We collected 267 GBM CEL files and normalized them relative to other microarrays of the same Affymetrix platform. 377 probesets on U133A and U133 Plus 2.0 arrays were used in a gene voting strategy with 177 probesets of matching genes on older U95Av2 arrays. Kaplan-Meier curves and Cox proportional hazard analyses were applied in distinguishing survival differences between expression subtypes and age. Results: Here we collected 267 glioblastomas and explore the relationship between gene expression subtype, age at diagnosis, and survival. This meta-analysis of published data in addition to new data confirms the existence of four distinct GBM expression-signatures. Further, patients with PN subtype GBMs had longer survival, as expected. However, the age of the patient at diagnosis is not predictive of survival time when controlled for the PN subtype. Conclusions: The survival benefit of younger age is nullified when patients are stratified by gene expression group. Thus, the main cause of the age effect in GBMs is the more frequent occurrence of PN GBMs in younger patients relative to older patients. Keywords: Gene expression profiling, GBM, glioblastoma, survival, MGMT, VEGFA, EGFR, Temozolomide, Affymetrix
-
02 GSE318645 对复发性胶质母细胞瘤患者进行手术时机试验,分别给予双免疫检查点阻断(nivolumab+ipilimumab)、单药 nivolumab 或安慰剂治疗。术后,双免疫检查点阻断组继续治疗,单药组治疗至疾病进展或不可接受毒性。从手术切除的肿瘤组织和多个时间点采集的外周血单核细胞(PBMCs)中提取 RNA,进行 RNA 测序,比较不同治疗组间肿瘤组织和 PBMCs 的转录特征差异。
设计对复发性胶质母细胞瘤患者进行手术时机试验,分别给予双免疫检查点阻断(nivolumab+ipilimumab)、单药 nivolumab 或安慰剂治疗。术后,双免疫检查点阻断组继续治疗,单药组治疗至疾病进展或不可接受毒性。从手术切除的肿瘤组织和多个时间点采集的外周血单核细胞(PBMCs)中提取 RNA,进行 RNA 测序,比较不同治疗组间肿瘤组织和 PBMCs 的转录特征差异。
摘要We conducted a surgical window-of-opportunity trial (NCT04606316) in 63 patients with relapsed, resectable glioblastoma. Participants received either dual PD-1+CTLA-4 immune checkpoint blockade (ICB) with nivolumab+ipilimumab (Arm 1), nivolumab alone (Arm 2), or placebo (Arm 3) before resection. Following surgery, Arms 1 and 3 received dual ICB, while Arm 2 received nivolumab until progression or unacceptable toxicity. Median overall survival was 402 days (95% CI, 265–543) in patients who received dual ICB and 276 days (95% CI, 166–698) for patients who received nivolumab alone. Dual ICB elicited robust intratumoral and systemic immune activation characterized by the highest tumor-infiltrating lymphocyte (TIL) density and greater interferon-related gene expression in the blood. TIL density strongly correlated with survival outcomes, while tumor mutational burden did not. Blood transcriptional profiling revealed that early interferon signature upregulation after neoadjuvant therapy predicted improved survival, whereas sustained elevation during adjuvant treatment correlated with poorer outcomes. Our results demonstrate the clear pharmacodynamic activity of dual ICB in glioblastoma, with survival outcomes comparing favorably to similar studies.
-
03 GSE4271 对77例原发性高级别星形细胞瘤和23例匹配的复发性高级别星形细胞瘤进行基因表达分析,以识别与生存期和疾病进展相关的基因表达变化。研究对象为WHO分级III和IV的星形细胞瘤,包含广泛的生存时间范围。
设计对77例原发性高级别星形细胞瘤和23例匹配的复发性高级别星形细胞瘤进行基因表达分析,以识别与生存期和疾病进展相关的基因表达变化。研究对象为WHO分级III和IV的星形细胞瘤,包含广泛的生存时间范围。
摘要Novel prognostic subclasses of high-grade astrocytoma are identified and discovered to resemble stages in neurogenesis. One tumor class displaying neuronal lineage markers shows longer survival, while two tumor classes enriched for neural stem cell markers display equally short survival. Poor prognosis subclasses exhibit either markers of proliferation or of angiogenesis and mesenchyme. Analysis of gene expression data is described in Phillips et al., Cancer Cell, 2006. Keywords: Disease state comparison
-
04 GSE139533 对原发性及复发性胶质母细胞瘤(GB)组织和GB来源的干细胞进行RNA测序分析,比较其转录特征变化,并基于基因表达数据模拟130种抗癌药物的疗效,评估复发性肿瘤组织和分离的GB干细胞对替莫唑胺的敏感性变化。
设计对原发性及复发性胶质母细胞瘤(GB)组织和GB来源的干细胞进行RNA测序分析,比较其转录特征变化,并基于基因表达数据模拟130种抗癌药物的疗效,评估复发性肿瘤组织和分离的GB干细胞对替莫唑胺的敏感性变化。
摘要We investigated longitudinal transcriptomic patterns associated with glioblastoma (GB) recurrence by integrative approach utilizing multisampling strategy, RNA sequencing and complementary investigations of tumor tissues and GB stem cells. In total, 128 tissue samples of 44 tumors including 23 first diagnosed, 19 recurrent and 2 secondary recurrent GBs were analyzed in parallel with 27 primary cultures of GB stem cells. We found that intratumoral transcriptomic heterogeneity is an intrinsic characteristic that is conserved in newly diagnosed and recurrent GBs and captured in GB stem cells. We revealed a high degree of concordance between GB tumor tissues and stem cells in the longitudinal transcriptomic changes associated with tumor recurrence. We used gene expression data to model the efficacy of 130 anti-cancer drugs. For the recurrent tumor tissues and isolated GB stem cells we showed dramatically reduced simulated sensitivities to the first line chemotherapeutic temozolomide. In turn, several therapeutics including immune checkpoint inhibitors were predicted to be more effective in the recurrence setting. Our results strongly suggest that the spectrum of potentially effective drugs may differ between newly diagnosed and recurrent glioblastomas and provides a transcriptional rationale for the lack of significant therapeutic benefit from temozolomide in patients with recurrent GB.
-
06 GSE72951 对复发性胶质母细胞瘤(GBM)患者使用福尔马林固定石蜡包埋(FFPE)肿瘤组织进行基因表达分析,以识别可能从贝伐珠单抗(Beva)和卡莫司汀(CCNU)联合治疗中获益的患者。研究采用随机分组,将患者分为接受贝伐珠单抗单药治疗、卡莫司汀单药治疗或联合治疗的三组,通过 DASL 和 RNA-seq 技术检测基因表达,比较不同治疗组的进展无病生存期(PFS)和总生存期(OS)差异。
设计对复发性胶质母细胞瘤(GBM)患者使用福尔马林固定石蜡包埋(FFPE)肿瘤组织进行基因表达分析,以识别可能从贝伐珠单抗(Beva)和卡莫司汀(CCNU)联合治疗中获益的患者。研究采用随机分组,将患者分为接受贝伐珠单抗单药治疗、卡莫司汀单药治疗或联合治疗的三组,通过 DASL 和 RNA-seq 技术检测基因表达,比较不同治疗组的进展无病生存期(PFS)和总生存期(OS)差异。
摘要The results from the randomized phase II BELOB trial provided evidence for a potential benefit of bevacizumab (beva; a humanized monoclonal antibody against circulating VEGF-A) when added to CCNU chemotherapy in recurrent GBM patients. In this study, we have performed gene expression profiling (DASL and RNA-seq) on formalin fixed, paraffin embedded (FFPE) tumor material from patients treated within the BELOB trial to identify recurrent GBM patients who benefit most from combined beva/CCNU treatment. We first extensively validate the use of FFPE tissues for expression profiling on both DASL and RNA-seq. Our data show that tumors assigned to IGS-18 or ‘classical’ GBMs show a significant benefit in progression free survival (PFS) and a trend towards benefit in overall survival (OS) from beva+CCNU treatment; other subtypes do not show such benefit. In particular, expression of FMO4 and OSBPL3 were associated with treatment response. All molecular glioma subtypes are evenly distributed along the different study arms and the improved outcome in the beva/CCNU arm therefore is not explained by an uneven distribution of prognostically favorable subtypes. Analysis of RNA-seq data highlighted genetic changes, including mutations, gene fusions (and identification of the exact genomic breakpoint), and copy number changes (albeit with limited resolution) within this well-defined cohort of tumors. When validated in an independent dataset, the predictive markers identified in this study will allow selection of recurrent GBM patients that benefit from beva+CCNU treatment.
-
07 GSE177549 对84例原发性或复发性胶质母细胞瘤患者组织核心进行总RNA提取,采用NanoString基因表达检测技术,使用包含4个管家基因和30个分类基因的定制探针集分析,识别经典(CL)、间质型(MES)、成纤维型(PN)和神经型(NL)亚型,比较不同亚型间的基因表达差异。
-
08 GSE222515 对胶质母细胞瘤患者在诊断(Primary)和复发(Recurrent)时的肿瘤样本进行RNA测序,比较两者的基因表达特征,分析EGFR扩增状态对通路活性的影响。
设计对胶质母细胞瘤患者在诊断(Primary)和复发(Recurrent)时的肿瘤样本进行RNA测序,比较两者的基因表达特征,分析EGFR扩增状态对通路活性的影响。
摘要Background: Glioblastoma mortality is driven by tumour progression or recurrence despite administering a therapeutic arsenal consisting of surgical resection, radiation, and alkylating chemotherapy. The genetic changes underlying tumour progression and chemotherapy resistance are poorly understood. Methods: In this work, we sought to define the relationship between EGFR amplification status, EGFR mRNA expression, and EGFR pathway activity. We compared RNA-sequencing data from matched primary and recurrent tumour samples (N = 40 patients, 20 with EGFR amplification). Results: In the setting of glioblastoma recurrence, the EGFR pathway was overexpressed regardless of EGFR amplification status, suggesting a common genomic endpoint in recurrent glioblastoma, although EGFR amplification did associate with higher EGFR mRNA expression. Three of forty patients in the study cohort had EGFR-amplified tumours and received targeted EGFR therapy. Their molecular subtypes and clinical outcomes did not significantly differ from patients who received conventional chemotherapy. Conclusion: Our findings suggest that while the EGFR amplification may confer a unique molecular profile in primary glioblastoma, pathway analysis reveals upregulation of the EGFR pathway in recurrence, regardless of amplification status. As such, the EGFR pathway may be a key mediator of glioblastoma progression.
-
09 GSE155434 对29例原发-复发配对的人类胶质母细胞瘤样本进行RNA测序,同时分析非恶性成人及胎儿脑组织样本,比较不同阶段的剪接模式差异,并利用单细胞RNA测序数据筛选细胞类型特异性剪接事件。
设计对29例原发-复发配对的人类胶质母细胞瘤样本进行RNA测序,同时分析非恶性成人及胎儿脑组织样本,比较不同阶段的剪接模式差异,并利用单细胞RNA测序数据筛选细胞类型特异性剪接事件。
摘要Alternative splicing is a rich source of tumor-specific neoantigen targets for immunotherapy. This holds promise for glioblastomas (GBMs), the most common primary tumors of the adult brain, which are resistant to standard-of-care therapy. Although most clinical trials enroll patients at recurrence, most preclinical studies have been done with specimens from primary disease. There are limited expression data from GBMs at recurrence and surprisingly little is known about the evolution of splicing patterns under therapy. We profiled 29 primary-recurrent paired human GBM specimens via RNA sequencing. We describe the landscape of alternative splicing in GBM at recurrence and contrast that to primary and non-malignant brain-tissue specimens. By screening single-cell atlases, we identify cell-type specific splicing patterns and novel splicing events in cell-surface proteins that are suitable targets for engineered T-cell therapies. We identify recurrent-specific isoforms of mitogen-activated kinase pathway genes that enhance invasiveness and are preferentially expressed by stem-like cells. These studies shed light on gene expression in recurrent GBM and identify novel targets for therapeutic development.
-
10 GSE79671 对复发性胶质母细胞瘤患者的肿瘤样本进行RNA-seq,分组为应答组和非应答组,每组分别在治疗前和治疗后采集样本,进行配对分析,同时比较应答组与非应答组治疗前的转录差异。
设计对复发性胶质母细胞瘤患者的肿瘤样本进行RNA-seq,分组为应答组和非应答组,每组分别在治疗前和治疗后采集样本,进行配对分析,同时比较应答组与非应答组治疗前的转录差异。
摘要Purpose: To identify transcriptional changes by RNA-seq in tumor samples, before bevacizumab combination treatment and after bevacizumab combination treatment in both responding and non-responding recurrent glioblastoma patients
-
11 GSE254873 本研究分析了17位患者匹配的原发性(pGBM)和复发性(rGBM)胶质母细胞瘤肿瘤的总RNA,采用NanoString Human nCounter Neuroinflammation面板进行基因表达分析,比较原发与复发肿瘤的转录组差异,并根据复发时间(STTR vs LTTR)分组,检测与肿瘤复发相关的基因表达变化。
设计本研究分析了17位患者匹配的原发性(pGBM)和复发性(rGBM)胶质母细胞瘤肿瘤的总RNA,采用NanoString Human nCounter Neuroinflammation面板进行基因表达分析,比较原发与复发肿瘤的转录组差异,并根据复发时间(STTR vs LTTR)分组,检测与肿瘤复发相关的基因表达变化。
摘要Introduction: Glioblastoma (GBM) is a lethal brain tumor without effective treatment options. Here, we sought to characterize longitudinal tumor immune microenvironment (iTME) changes in order to find potential actionable targets to prevent GBM-induced immune evasion mechanisms. This study included 15 patient-matched treatment-naïve (primary, pGBM, WHO grade 4) and recurrent (rGBM) IDH1 wild type tumors. Methods: Extracted RNA and proteins from fresh frozen tumor samples from matched pGBM and rGBM were profiled via transcriptomics and proteomics, respectively. Paired formalin-fixed paraffin-embedded tumor samples were processed for spatial transcriptomics analysis. Results: Differentially expressed genes and proteins between pGBM and rGBM were involved in pathways responsible for synapse development and myelination which have been shown to play a role in GBM recurrence. By categorizing patients into short and long time-to-relapse (STTR vs LTTR), and by correlating TTR with gene expression, we detected genes positively or negatively associated with tumor relapse. Expression of FCG receptor and complement system genes such as FCGR1A (CD64), FCGR3A (CD16a) and the complement C3 were negatively correlated with STTR, whereas high expression of DNMT1/3A, and SMARCA4, involved in DNA methylation, were positively correlated with LTTR. Spatial transcriptomic analysis of the tumor cells compartment defined by GFAP expression showed enrichment in the proportion of oligodendrocytes in recurrent tumors in rGBM, whereas CD64-positive myeloid cell compartment showed a switch of quiescent to activated microglia, appearance of B cells and a reduction in macrophage proportion in recurrent tumors with STTR. Conclusion: Our results uncover a role of CD64-expressing myeloid cells, mostly activated microglia, in GBM recurrence and suggest that interfering with these cells may represent a new therapeutic option for preventing GBM relapse.
-
12 GSE254874 对17位患者匹配的原发性(pGBM)和复发性(rGBM)胶质母细胞瘤肿瘤样本进行转录组学和蛋白质组学分析,同时对福尔马林固定石蜡包埋的肿瘤样本进行空间转录组分析,比较原发与复发肿瘤的基因表达及蛋白差异,以及根据复发时间(短时间 vs 长时间)分类后的差异。每个患者包含两个样本,分别对应原发和复发状态,样本通过RNAlater保存,RNA提取使用AllPrep mini Kit,检测采用NanoString Human nCounter PanCancer IO 360 Panel。
设计对17位患者匹配的原发性(pGBM)和复发性(rGBM)胶质母细胞瘤肿瘤样本进行转录组学和蛋白质组学分析,同时对福尔马林固定石蜡包埋的肿瘤样本进行空间转录组分析,比较原发与复发肿瘤的基因表达及蛋白差异,以及根据复发时间(短时间 vs 长时间)分类后的差异。每个患者包含两个样本,分别对应原发和复发状态,样本通过RNAlater保存,RNA提取使用AllPrep mini Kit,检测采用NanoString Human nCounter PanCancer IO 360 Panel。
摘要Introduction: Glioblastoma (GBM) is a lethal brain tumor without effective treatment options. Here, we sought to characterize longitudinal tumor immune microenvironment (iTME) changes in order to find potential actionable targets to prevent GBM-induced immune evasion mechanisms. This study included 15 patient-matched treatment-naïve (primary, pGBM, WHO grade 4) and recurrent (rGBM) IDH1 wild type tumors. Methods: Extracted RNA and proteins from fresh frozen tumor samples from matched pGBM and rGBM were profiled via transcriptomics and proteomics, respectively. Paired formalin-fixed paraffin-embedded tumor samples were processed for spatial transcriptomics analysis. Results: Differentially expressed genes and proteins between pGBM and rGBM were involved in pathways responsible for synapse development and myelination which have been shown to play a role in GBM recurrence. By categorizing patients into short and long time-to-relapse (STTR vs LTTR), and by correlating TTR with gene expression, we detected genes positively or negatively associated with tumor relapse. Expression of FCG receptor and complement system genes such as FCGR1A (CD64), FCGR3A (CD16a) and the complement C3 were negatively correlated with STTR, whereas high expression of DNMT1/3A, and SMARCA4, involved in DNA methylation, were positively correlated with LTTR. Spatial transcriptomic analysis of the tumor cells compartment defined by GFAP expression showed enrichment in the proportion of oligodendrocytes in recurrent tumors in rGBM, whereas CD64-positive myeloid cell compartment showed a switch of quiescent to activated microglia, appearance of B cells and a reduction in macrophage proportion in recurrent tumors with STTR. Conclusion: Our results uncover a role of CD64-expressing myeloid cells, mostly activated microglia, in GBM recurrence and suggest that interfering with these cells may represent a new therapeutic option for preventing GBM relapse.
-
13 GSE121810 对复发性胶质母细胞瘤患者进行术前或术后 pembrolizumab 治疗,采集手术新鲜肿瘤组织的总 RNA 进行 RNA-Seq,比较两种治疗时机对肿瘤转录组的影响。
设计对复发性胶质母细胞瘤患者进行术前或术后 pembrolizumab 治疗,采集手术新鲜肿瘤组织的总 RNA 进行 RNA-Seq,比较两种治疗时机对肿瘤转录组的影响。
摘要Glioblastoma is the most common primary malignant brain tumor in adults and associated with poor survival. Standard-of-care chemotherapy and radiation confer a median overall survival of under two years. The Ivy Foundation Early Phase Clinical Trials Consortium conducted a randomized, multi institution clinical trial to evaluate immune responses and survival following neoadjuvant and/or adjuvant therapy with pembrolizumab, a programmed cell death protein 1 (PD-1) monoclonal antibody, in 35 patients with recurrent, surgically resectable glioblastoma. Patients who were randomized to receive neoadjuvant pembrolizumab, with continued adjuvant therapy following surgery, had significantly extended overall survival compared to patients that were randomized to receive adjuvant, post-surgical PD-1 blockade alone (hazard ratio = 0.39; P = 0.04, log-rank test). Neoadjuvant PD-1 blockade was associated with upregulation of T cell and interferon-γ-related genes, but downregulation of cell cycle related genes within the tumor, which was not seen in patients that received adjuvant therapy alone. Focal induction of programmed death-ligand 1 (PD-L1) in the tumor microenvironment was observed more frequently in the neoadjuvant group than in tumors obtained from patients treated only in the adjuvant setting. Similarly, neoadjuvant pembrolizumab was associated with clonal T cell expansion and the overlap of T cell receptors between tumor and blood, decreased PD-1 expression in T cells and a decreasing peripheral monocytic population. These findings suggest that the neoadjuvant administration of PD-1 blockade enhances the local and systemic anti-tumor immune response and may represent a more efficacious approach to the treatment of this uniformly lethal brain tumor. This trial was registered with ClinicalTrials.gov under the identifier NCT02852655 (https://clinicaltrials.gov/ct2/show/NCT02852655).
-
14 GSE339484 对14名胶质瘤患者的配对原发与复发组织样本进行bulk RNA测序,按2021年WHO分类标准,11例IDH1 wt、CNS WHO grade 4病例作为主要研究组,3例IDH1 mutant、grade 3病例作为对照组,比较各患者原发与复发肿瘤的转录组差异,并分析差异基因的功能富集与通路特征。
设计对14名胶质瘤患者的配对原发与复发组织样本进行bulk RNA测序,按2021年WHO分类标准,11例IDH1 wt、CNS WHO grade 4病例作为主要研究组,3例IDH1 mutant、grade 3病例作为对照组,比较各患者原发与复发肿瘤的转录组差异,并分析差异基因的功能富集与通路特征。
摘要Glioma recurrence remains a major clinical challenge and is associated with poor patient outcomes. To characterize transcriptomic alterations associated with tumor recurrence, we performed bulk RNA sequencing on paired primary and recurrent glioma tissue specimens from 14 patients. According to the 2021 World Health Organization (WHO) Classification of Central Nervous System Tumors, glioblastoma is defined as IDH-wildtype (IDH-wt), CNS WHO grade 4. Based on these criteria, 11 paired cases were classified as glioblastoma (IDH-wt, grade 4), while three paired cases with IDH-mutant, grade 3 gliomas were included as a comparison group. Differential gene expression analysis was performed between paired primary and recurrent tumors to identify recurrence-associated transcriptomic changes. Functional enrichment and pathway analyses were subsequently conducted to investigate the biological processes and signaling pathways associated with the identified differentially expressed genes (DEGs). This dataset provides a resource for exploring the molecular mechanisms underlying glioma recurrence and may facilitate the identification of potential therapeutic targets and biomarkers associated with disease progression.
-
15 GSE327275 对81名经活检确认的复发性恶性胶质瘤患者进行单臂、单中心、开放标签的I期试验,评估D2C7-ATC单次输注治疗增强型疾病的效果。研究对象为脑肿瘤组织,采集时间为治疗前,采用RNA提取并进行RNA-Seq检测,主要比较不同EGFR表达水平与生存时间的关系。
设计对81名经活检确认的复发性恶性胶质瘤患者进行单臂、单中心、开放标签的I期试验,评估D2C7-ATC单次输注治疗增强型疾病的效果。研究对象为脑肿瘤组织,采集时间为治疗前,采用RNA提取并进行RNA-Seq检测,主要比较不同EGFR表达水平与生存时间的关系。
摘要Recurrent glioblastoma (rGBM) has a dismal prognosis and is frequently characterized by epidermal growth factor receptor (EGFR) alterations. D2C7-ATC is a recombinant antibody-toxin conjugate (ATC) targeting wild-type EGFR and mutant EGFR variant III (EGFRvIII). We conducted a single-arm, single-site, open-label Phase 1 trial evaluating a single infusion of D2C7-ATC via convection-enhanced delivery in the enhancing disease of 81 patients with biopsy-confirmed recurrent malignant glioma. The primary objective of the trial was to determine the toxicity and the recommended phase 2 dose (RP2D) of D2C7-ATC. Secondary objectives included the description of overall survival (OS) and the assessment of the association between EGFR expression and OS. The median OS [mOS] was 9.5 months among 81 patients with recurrent malignant glioma, which included 43 patients in the dose-escalation stage (40 to 35,032 ng/mL) and 38 in the dose-expansion stage (at the RP2D of 6,920 ng/mL). Among patients with isocitrate dehydrogenase (IDH) wild-type (wt) rGBM (N=72), 35% (N=25), 24% (N=17), and 11% (N=8) survived longer than 12, 15, and 20 months, respectively, and three achieved durable radiographic partial responses lasting 54, 34, and 28 months. D2C7-ATC was generally well tolerated, with mainly grade 1–2 treatment-related adverse events (67%). Adverse events were predominantly neurologic and were associated with the location of the infused, enhancing recurrent tumor as well as secondary reactive peritumoral inflammation. The maximum tolerated dose was exceeded at 35,032 ng/mL after two patients experienced dose-limiting toxicity (grade 4 cerebral edema, N=1; grade 3 dysphasia, N=1). In the group of IDHwt rGBM patients with available tumor and plasma samples (N=27), univariate analyses identified survival-associated biomarkers, including tumor EGFR expression, a tumor inflammatory gene signature (CXCL8, CCL20, IL1A, CSF2, CCL2, IL6, IL1R1), and circulating cytokines (MIP-3b, PD-L1, GM-CSF, IL-8, VEGF). Importantly, IDHwt rGBM patients with low EGFR expression in pre-treatment tumor had a mOS of 13 months (P = 0.09), while those with low IL-18 in post-treatment plasma had a mOS of 16.6 months (P = 0.0008). The trial met all primary and secondary objectives. Reverse translational studies in the CT2A-EGFRvIII syngeneic model implicated neutrophils and neutrophil extracellular traps in mediating antitumor responses. These findings indicate that EGFR-targeted D2C7-ATC therapy prolongs survival in a subset of patients with IDHwt rGBM via intratumoral and systemic immune activation, and provide a mechanistic rationale for further evaluation in a larger cohort of patients with IDHwt rGBM. ClinicalTrials.gov registration: NCT02303678.
-
16 GSE11100 对胶质母细胞瘤复发肿瘤患者术前及术后肿瘤组织进行微阵列分析,同时纳入未接受树突状细胞疫苗的患者术前术后肿瘤作为对照,比较疫苗处理与未处理组肿瘤的基因表达差异。
设计对胶质母细胞瘤复发肿瘤患者术前及术后肿瘤组织进行微阵列分析,同时纳入未接受树突状细胞疫苗的患者术前术后肿瘤作为对照,比较疫苗处理与未处理组肿瘤的基因表达差异。
摘要Human Glioblastoma Multiforme tumors taken before dendritic cell vaccination, the recurrent tumors taken after vaccination and control GBM tumors from non vaccinated patients. Keywords: Disease State Analysis
-
17 GSE264695 对复发性胶质母细胞瘤患者的肿瘤组织进行bulk-RNA测序,处理为新辅助pembrolizumab,比较处理组与未处理组的基因表达差异。
设计对复发性胶质母细胞瘤患者的肿瘤组织进行bulk-RNA测序,处理为新辅助pembrolizumab,比较处理组与未处理组的基因表达差异。
摘要Glioblastoma is immunologically “cold” and resistant to single-agent immune-checkpoint inhibitors (ICI). Our previous study of neoadjuvant pembrolizumab in surgically-accessible recurrent glioblastoma identified a molecular signature of response to ICI and suggested that neoadjuvant pembrolizumab may improve survival. To increase the power of this observation, we performed bulk-RNA seq on resected tumor tissue in an additional 25 patients with surgically-accessible recurrent glioblastoma. Neoadjuvant pembrolizumab was associated with suppression of cell cycle/cancer proliferation genes and upregulation of T-cell/interferon-related gene expression. This signature was unique to patients treated with neoadjuvant pembrolizumab and was an independent risk factor for survival. Our results demonstrate a clear pharmacodynamic effect of anti-PD1 therapy in glioblastoma and identify pathways that may mediate resistance. However, we did not confirm a survival benefit to neoadjuvant pembrolizumab in recurrent glioblastoma. Our new data suggests some patients may exhibit innate resistance to pre-surgical ICI and require other concomitant therapies to sensitize effectively.
-
18 GSE145128 对患者来源和实验生成的 IDH wt 胶质母细胞瘤样本进行配对分析(治疗前与复发),使用微阵列检测基因表达,比较治疗前与复发样本的差异。
设计对患者来源和实验生成的 IDH wt 胶质母细胞瘤样本进行配对分析(治疗前与复发),使用微阵列检测基因表达,比较治疗前与复发样本的差异。
摘要Glioblastoma therapy relies on the alkylating drug temozolomide (TMZ) administered to irradiated patients post-neurosurgery, which increases overall survival but cannot prevent fatal disease relapse. Using clinical samples and glioblastoma models, we here identify TMZ-driven enrichment of ALDH1A1+ tumor subclones acquiring AKT-dependent drug resistance en route to relapse. We demonstrate that this recurrent phenotype switch is predictable and can be countered by a sequential rather than simultaneous combinatorial treatment approach.
-
19 GSE207753 对复发性胶质母细胞瘤患者进行治疗前的mRNA表达分析,使用NanoString nCounter PanCancer Immune Profiling panel和qRT-PCR检测肿瘤-免疫微环境,分组为治疗反应组(Responder)和非反应组(Non-responder),比较两组的基因表达差异。
设计对复发性胶质母细胞瘤患者进行治疗前的mRNA表达分析,使用NanoString nCounter PanCancer Immune Profiling panel和qRT-PCR检测肿瘤-免疫微环境,分组为治疗反应组(Responder)和非反应组(Non-responder),比较两组的基因表达差异。
摘要Glioblastoma multiforme (GBM) is the most common and aggressive primary malignant brain tumor, but the current therapeutic approaches have very limited impact on increase of the patients’s survival with GBM. Our recent clinical trial with autologous activated nature killer (NK) cells (AKCs) including 14 patients with recurrent GBM found that the progression-free and overall survival times were significantly increased in some patients in the treatment group. In the present study, we identified TNFRSF18, TNFSF4, and IL12RB2 as biomarkers that predict response to NK cell therapeutics by studying the tumor-immune microenvironment using NanoString and qRT-PCR analyses. In addition, our results show that responders to NK therapy have an immune-activated tumor microenvironment, whereas non-responders do not. Considering that immune and inflammatory response-enrichment is related to the high-risk group in this tumor type, our findings highlight a new treatment strategy of NK cell therapeutics for patients with highly aggressive recurrent GBM.
-
20 GSE115459 研究对象为胶质母细胞瘤复发患者的肿瘤组织及对应的星形胶质细胞,采集自肿瘤水肿区。将三名患者的原发胶质母细胞瘤组织、复发胶质母细胞瘤组织及星形胶质细胞分别作为样本,通过microarray检测总RNA中的lncRNA表达谱,比较不同组织类型的lncRNA表达差异。
设计研究对象为胶质母细胞瘤复发患者的肿瘤组织及对应的星形胶质细胞,采集自肿瘤水肿区。将三名患者的原发胶质母细胞瘤组织、复发胶质母细胞瘤组织及星形胶质细胞分别作为样本,通过microarray检测总RNA中的lncRNA表达谱,比较不同组织类型的lncRNA表达差异。
摘要Glioblastoma (GBM) remains among the most lethal brain tumors despite improvements in treatment. Surgical resection is a universal component of glioma therapy. However, the mechanism underlying postoperative recurrence remains a challenge due to limited information regarding the changes that occur in the postoperative microenvironment. Here, we show that a subtype of proinflammatory reactive astrocytes designated is induced by inflammatory cytokines or injury. We show that reactive astrocytes can secrete the long noncoding RNA (lncRNA) LOC646762 to promotes recurrence glioblastoma proliferation in an exosome-dependent manner.We firstly named this reactive astrocyte associated lnRNA as “lnc-RVT1”.
-
21 GSE162643 对6名复发性胶质母细胞瘤患者在G207接种前和接种后(2-5天内)采集的脑肿瘤组织进行RNA测序,比较接种前后基因表达差异。按总单位数与组数估计,共9个样本,分为接种前和接种后两组。
设计对6名复发性胶质母细胞瘤患者在G207接种前和接种后(2-5天内)采集的脑肿瘤组织进行RNA测序,比较接种前后基因表达差异。按总单位数与组数估计,共9个样本,分为接种前和接种后两组。
摘要We have previously developed the use of genetically engineered herpes simplex virus type 1 ("G207") for the experimental treatment of malignant glioma (PMID: 18957964). We demonstrated that G207 propagates in and kills nervous system tumor cells with little to no evidence of viral encephalitis. Here, six adult patients with recurrent glioblastoma were recruited onto a phase Ib clinical trial to test G207 safety and efficacy in anti-tumor response. We obtained resected tumor tissue before and after (within 2-5 days) inoculation with G207. RNA was extracted from all tissues and subject to library preparation for RNA sequencing on Illumina instrumentation.
-
22 GSE255754 对复发性高分级胶质瘤患者肿瘤样本进行分组,设置2.5 mg、5 mg、10 mg剂量组及三个对照组,采用poly-A RNA纯化法提取mRNA,制备并测序文库,通过RNA-Seq分析比较各剂量组与对照组间雌二醇合成及DNA损伤通路的差异。
设计对复发性高分级胶质瘤患者肿瘤样本进行分组,设置2.5 mg、5 mg、10 mg剂量组及三个对照组,采用poly-A RNA纯化法提取mRNA,制备并测序文库,通过RNA-Seq分析比较各剂量组与对照组间雌二醇合成及DNA损伤通路的差异。
摘要High grade gliomas (HGGs) remain highly fatal malignancies with glioblastoma accounting for almost 50% of primary brain malignancies in the elderly. Unfortunately, despite the use of multiple treatment modalities, the prognosis remains poor in this population. Our pre-clinical studies suggest that the expression of CYP19A1, that encodes aromatase, is significantly upregulated in HGGs and that letrozole (LTZ), an FDA approved aromatase inhibitor, has marked activity against HGGs. We conducted a phase 0/I single center clinical trial to assess the tumoral availability, pharmacokinetics (PK), safety and tolerability of LTZ in recurrent HGG patients. Planned dose cohorts included 2.5, 5, 10, 12.5, 15, 17.5 and 20 mg of LTZ administered daily pre- and post-surgery or biopsy. Tumor samples were assayed for LTZ content and relevant biomarkers. LTZ caused dose-dependent inhibition of estradiol synthesis and modulated DNA damage pathways in tumor tissues as evident using RNA-seq analysis.
-
23 GSE195682 对处于最小残留疾病(MRD)状态的vehicle-treated和chemoradiotherapy-treated BT799及MBT06人胶质母细胞瘤细胞系进行单细胞RNA测序,分析治疗后克隆群体的进化轨迹差异。
设计对处于最小残留疾病(MRD)状态的vehicle-treated和chemoradiotherapy-treated BT799及MBT06人胶质母细胞瘤细胞系进行单细胞RNA测序,分析治疗后克隆群体的进化轨迹差异。
摘要Recurrence of solid tumors renders patients vulnerable to a distinctly advanced, highly treatment-refractory disease state that has an increased mutational burden and novel oncogenic drivers not detected at initial diagnosis. Improving outcomes for recurrent cancers requires a better understanding of cancer cell populations that expand from the post-therapy, minimal residual disease (MRD) state. We profiled barcoded tumor cell populations through therapy at tumor initiation/engraftment, MRD and recurrence in our therapy-adapted, patient-derived xenograft models of glioblastoma (GBM). Tumors showed distinct patterns of recurrence in which clonal populations exhibited either an a priori, pre-existing fitness advantage, or a priori equipotency fitness acquired through therapy. Characterization of the MRD state by single-cell and bulk RNA sequencing revealed a tumor-intrinsic immunomodulatory signature with strong prognostic significance at the transcriptomic level and in proteomic analysis of cerebrospinal fluid (CSF) collected from GBM patients at all stages of disease. Our results provide insight into the innate and therapy-driven dynamics of human GBM, and the prognostic value of interrogating the MRD state in solid cancers.
人源·鼠源单细胞
Human · Mouse · Single-cell
-
01 GSE174554 对80例IDH野生型胶质母细胞瘤(GBM)样本进行单核RNA测序,其中40例为原发肿瘤,40例为患者匹配的复发肿瘤。部分队列还通过单细胞ATAC测序、单细胞数字空间和单细胞空间转录组测序进行分析。所有患者仅接受标准治疗:替莫唑胺、放疗和手术切除。研究对象为人类脑组织,样本按复发与原发分组,比较两组间细胞组成差异,包括Verhaak表型细胞比例变化及肿瘤浸润单核细胞来源变化。
设计对80例IDH野生型胶质母细胞瘤(GBM)样本进行单核RNA测序,其中40例为原发肿瘤,40例为患者匹配的复发肿瘤。部分队列还通过单细胞ATAC测序、单细胞数字空间和单细胞空间转录组测序进行分析。所有患者仅接受标准治疗:替莫唑胺、放疗和手术切除。研究对象为人类脑组织,样本按复发与原发分组,比较两组间细胞组成差异,包括Verhaak表型细胞比例变化及肿瘤浸润单核细胞来源变化。
摘要Most clinical trials for glioblastoma (GBM) enroll patients at recurrence. However, most pre-clinical animal models are of primary disease. Most studies have used tissues from primary tumors. Knowledge of GBM cellular composition at recurrence is limited. We profiled 80 human IDH-wild-type GBM specimens via single-nucleus RNA sequencing, 40 primary tumors and 40 patient-matched recurrent tumors. Select cohorts were also profiled via single-cell assay for transposase-accessible chromatin, single-cell digital-spatial, and single-cell spatial-transcriptomic assays. All patients were treated only with standard-of-care therapy: temozolomide, radiation and surgical resection. The cohort had a 1.2 male/female ratio, ages 35–76. We found a significant increase at recurrence in cells with the Verhaak mesenchymal phenotype and fewer proneural cells. Although there was an increase in the percentage of cycling cells overall, the fraction of cycling proneural cells decreased while the fraction of cycling mesenchymal cells increased. These changes were concomitant with a significant increase in the percentage of tumor-infiltrating monocytic-lineage cells derived from the periphery. Taken together, these findings support a proneural-to-mesenchymal shift at recurrence due to an increase in the birth rate of mesenchymal cells, supported by an expansion of myeloid-derived cells from peripheral blood. Although the percentages of glioblastoma-infiltrating T-cells are generally low (~1% on average in our data), we found a statistically significant increase in T-cell abundance at recurrence. We identified a cohort of T-cell outliers that demonstrate 2-to-8-fold increases in T-cells over average levels. We validated that T-cells in these tumors have extravasated beyond the perivascular space and into the cellular tumor via immunohistochemistry and spatial profiling. We present our ongoing analysis of the paracrine signals, upstream transcription-factor expression, and cis-regulatory grammars utilized in immune-outlier GBMs. We describe how these programs change under therapy. These studies shed light on the effect of standard therapy in shaping GBM composition at recurrence.
-
02 GSE235676 对胶质母细胞瘤复发患者及小鼠模型进行单细胞 RNA 测序和空间转录组学分析,比较新辅助抗 PD-1 治疗组、TMZ+RT 治疗组与未治疗对照组的免疫细胞特征差异。采集脑组织样本,采用 scRNA-seq 技术检测免疫调节分子表达,识别高表达 SIGLEC9 基因的单核细胞衍生肿瘤相关巨噬细胞亚群,并分析其在治疗应答与非应答群体中的分布特征。
设计对胶质母细胞瘤复发患者及小鼠模型进行单细胞 RNA 测序和空间转录组学分析,比较新辅助抗 PD-1 治疗组、TMZ+RT 治疗组与未治疗对照组的免疫细胞特征差异。采集脑组织样本,采用 scRNA-seq 技术检测免疫调节分子表达,识别高表达 SIGLEC9 基因的单核细胞衍生肿瘤相关巨噬细胞亚群,并分析其在治疗应答与非应答群体中的分布特征。
摘要The neoadjuvant immune checkpoint blockade therapy only benefits a limited fraction of glioblastoma multiforme (GBM) patients. Thus, targeting other immunomodulators on myeloid cells is an attractive therapeutic option. Here, we performed single-cell RNA sequencing and spatial transcriptomics of GBM patients treated with neoadjuvant anti-PD-1 therapy. We identified unique monocyte-derived tumor-associated macrophage (TAM) subpopulations with functional plasticity that highly expressed the immunosuppressive SIGLEC9 gene and preferentially accumulated in the non-responders to anti-PD-1 treatment. Deletion of Siglece (murine homologue) resulted in significantly restrained tumor development and prolonged survival in mouse models. Mechanistically, targeting Siglece directly activated both CD4+ T cells and CD8+ T cells through antigen presentation, secreted chemokines and co-stimulatory factor interactions. Furthermore, Siglece deletion synergized with anti-PD-1/PD-L1 treatment to improve antitumor efficacy. Our data demonstrated that Siglec-9 is an immune checkpoint molecule on macrophages that can be targeted to enhance anti-PD-1/PD-L1 therapeutic efficacy for GBM treatment.
-
03 GSE163120 对小鼠和人类的胶质母细胞瘤组织进行单细胞RNA和蛋白质测序,比较新诊断与复发阶段的髓系细胞动态,包括WT小鼠GL261胶质母细胞瘤、CCR2-KO小鼠GL261胶质母细胞瘤、WT小鼠GL261肿瘤携带全脑、人类新诊断Grade IV胶质母细胞瘤及复发性胶质母细胞瘤样本。研究通过单细胞多组学分析揭示髓系细胞在不同物种和疾病阶段的异质性及功能分化。
设计对小鼠和人类的胶质母细胞瘤组织进行单细胞RNA和蛋白质测序,比较新诊断与复发阶段的髓系细胞动态,包括WT小鼠GL261胶质母细胞瘤、CCR2-KO小鼠GL261胶质母细胞瘤、WT小鼠GL261肿瘤携带全脑、人类新诊断Grade IV胶质母细胞瘤及复发性胶质母细胞瘤样本。研究通过单细胞多组学分析揭示髓系细胞在不同物种和疾病阶段的异质性及功能分化。
摘要Glioblastomas are aggressive primary brain cancers that invariably recur as therapy-resistant tumors. Myeloid cells control glioblastoma malignancy, but their dynamics during disease progression remains poorly understood. By relying on single-cell RNA and protein profiling, we mapped the glioblastoma immune landscape in newly diagnosed and recurrent patients and in mouse tumors. This revealed a large and diverse myeloid compartment, with dendritic cell and macrophage populations that were conserved across species and were dynamic across disease stages. Tumor-associated macrophages (TAMs) consisted of microglia- or monocyte-derived populations, with both exhibiting additional heterogeneity, including subsets with conserved lipid and hypoxic signatures. Microglia- and monocyte-derived TAMs (Mo-TAMs) were self-renewing populations that competed for space and could be depleted via CSF1R blockade. Microglia-derived TAMs were predominant in newly diagnosed tumors but were outnumbered by Mo-TAMs upon recurrence, especially in hypoxic tumor environments. Our results unravel the glioblastoma myeloid landscape and provide a framework for future therapeutic interventions.
-
04 GSE346465 Glioblastoma (GBM) is the most common and deadly primary brain tumor in adults, characterized by diffuse infiltrative lesions, distinct oncogenic alterations, and a suppressive tumor immune microenvironment (TIME). These traits, however, are not fully recapitulated in current syngeneic murine glioma models, thereby limiting the pre-clinical development of effective therapies. Here, we developed murine GBM models with patient-specific mutations that shared striking resemblance with human disease. Mosaic analysis with dual-recombinase mediated cassette exchange (MADR) and CRISPR-Cas9 were leveraged to generate autochthonous tumor models with single-copy somatic transgenesis of murine epidermal growth factor receptor variant III (mEGFRvIII) and loss-of-function mutations commonly observed in GBM. Characterization of a model lacking Pten and Cdkn2a (mEGFRvIII-PC) via histopathologic analyses, functional assays, and single-cell RNA sequencing showed these tumors developed as diffuse, infiltrative lesions with ill-defined margins and a necrotic core. The TIME was primarily comprised of microglia with minimal lymphocyte infiltration, recapitulating patient tumors. Furthermore, these tumors displayed intrinsic resistance to immune checkpoint blockade, potentially due to poor myeloid cell antigen presentation and T cell priming. Additionally, mEGFRvIII-PC cells were the most resistant to antigen-specific T cell-induced cytotoxicity and simultaneously promoted T cell exhaustion, while murine interferon-γ (mIFN-γ) stimulation induced a greater response in vitro with enhanced upregulation of PD-L1 relative to MHC-I. In sum, these findings demonstrate the improved fidelity of the mEGFRvIII-PC model to patient tumors and support its use in developing and refining novel therapeutic paradigms for GBM.
摘要Glioblastoma (GBM) is the most common and deadly primary brain tumor in adults, characterized by diffuse infiltrative lesions, distinct oncogenic alterations, and a suppressive tumor immune microenvironment (TIME). These traits, however, are not fully recapitulated in current syngeneic murine glioma models, thereby limiting the pre-clinical development of effective therapies. Here, we developed murine GBM models with patient-specific mutations that shared striking resemblance with human disease. Mosaic analysis with dual-recombinase mediated cassette exchange (MADR) and CRISPR-Cas9 were leveraged to generate autochthonous tumor models with single-copy somatic transgenesis of murine epidermal growth factor receptor variant III (mEGFRvIII) and loss-of-function mutations commonly observed in GBM. Characterization of a model lacking Pten and Cdkn2a (mEGFRvIII-PC) via histopathologic analyses, functional assays, and single-cell RNA sequencing showed these tumors developed as diffuse, infiltrative lesions with ill-defined margins and a necrotic core. The TIME was primarily comprised of microglia with minimal lymphocyte infiltration, recapitulating patient tumors. Furthermore, these tumors displayed intrinsic resistance to immune checkpoint blockade, potentially due to poor myeloid cell antigen presentation and T cell priming. Additionally, mEGFRvIII-PC cells were the most resistant to antigen-specific T cell-induced cytotoxicity and simultaneously promoted T cell exhaustion, while murine interferon-γ (mIFN-γ) stimulation induced a greater response in vitro with enhanced upregulation of PD-L1 relative to MHC-I. In sum, these findings demonstrate the improved fidelity of the mEGFRvIII-PC model to patient tumors and support its use in developing and refining novel therapeutic paradigms for GBM.
鼠源单细胞
Mouse · Single-cell
-
01 GSE76184 对RCAS-tva转基因小鼠的原发性胶质瘤及放射治疗后复发的肿瘤进行单细胞转录组测序,分析不同时间点(T1为原发性肿瘤阶段,T2为放射治疗后早期复发阶段,T3为放射治疗后晚期复发阶段)的肿瘤细胞亚群异质性及转录组动态变化。
设计对RCAS-tva转基因小鼠的原发性胶质瘤及放射治疗后复发的肿瘤进行单细胞转录组测序,分析不同时间点(T1为原发性肿瘤阶段,T2为放射治疗后早期复发阶段,T3为放射治疗后晚期复发阶段)的肿瘤细胞亚群异质性及转录组动态变化。
摘要Radiation is the frontline treatment for malignant gliomas. Intra-tumoral heterogeneity has been proposed to grant cancer cells a superior trajectory and survival advantage to avoid therapeutic interventions including radiation. However, direct evidence to support the hypothesis via the transcriptome dynamics of glioma during radiation therapy is limited. The current study aim to measure the functional subpopulation dynamics before and after radiation treatment that assist the radiation resistance at single cell resolution. We investigate the single cell transcriptome and biological pathways of primary glioma mouse model and post-radiation early/late time point. Specifically, we used the RCAS mouse model for gliomas, which overexpress PDGFRA as the model. Using single cell transcriptome, for the first time, we confirmed the proneural classification of PDGFRA RCAS glioma mouse model and its heterogeneity. We found that recurrent dominant subpopulations are featured with elevated proliferation rate and hypoxia. In addition, we identified a subpopulation of radiation resistant cells in at early time points with elevated stemness. Lastly, the subpopulations composition undergoes large changes at late time point when the tumor recurred. Single cell transcriptome profiling of radiation treated mouse glioma mouse model identified tumor cell subpopulations dynamics. It provides novel insights into the molecular phenotype and biological functions of radiation resistant tumor cell population.
-
02 GSE266145 研究对象为胶质母细胞瘤微环境,材料包括PDG-p53和PDG-Ink4a基因型小鼠的原发与复发脑肿瘤样本,以及Microglia、Monocyte-derived macrophages、CD45+/−等不同细胞类型。分组基于基因型(PDG-p53 vs. PDG-Ink4a)、肿瘤状态(原发 vs. 复发)和处理条件(No Treatment vs. 5 x 2Gy Irradiation)。采用单细胞RNA测序技术,比较不同组别间肿瘤相关巨噬细胞亚群的代谢特征及免疫功能差异。
设计研究对象为胶质母细胞瘤微环境,材料包括PDG-p53和PDG-Ink4a基因型小鼠的原发与复发脑肿瘤样本,以及Microglia、Monocyte-derived macrophages、CD45+/−等不同细胞类型。分组基于基因型(PDG-p53 vs. PDG-Ink4a)、肿瘤状态(原发 vs. 复发)和处理条件(No Treatment vs. 5 x 2Gy Irradiation)。采用单细胞RNA测序技术,比较不同组别间肿瘤相关巨噬细胞亚群的代谢特征及免疫功能差异。
摘要Tumors growing in metabolically-challenged environments, such as glioblastoma in the brain, are particularly reliant on cross-talk with their tumor microenvironment (TME) to satisfy their high energetic needs. However, the intricacies of this metabolic interplay and the consequences on immune cell subset diversity and function remain largely unexplored. We interrogated the heterogeneity of the glioblastoma TME using single cell multi-omics analyses in preclinical glioblastoma mouse models and patient samples, and identified metabolically-rewired tumor-associated macrophage (TAM) subpopulations that fuel glioblastoma malignancy. These TAM subsets, termed lipid-laden macrophages (LLMs) to reflect their increased lipid metabolism activity and cholesterol storage, are epigenetically rewired, display immunosuppressive features and are enriched in the aggressive mesenchymal glioblastoma subtype. In response to TME-derived cues triggering liver-X-receptor (LXR) expression, macrophages increase engulfment of cholesterol-rich myelin debris and acquire an LLM phenotype. Subsequently, LLMs directly transfer myelin-derived lipids to cancer cells in an LXR/Abca1-dependent manner, thereby fueling the heightened metabolic demands of mesenchymal glioblastoma. Furthermore, LLM content predicts clinical outcomes and immune checkpoint blockade response in glioblastoma patients and other cancer types. Our work provides an in-depth understanding of the immune-metabolic interplay during glioblastoma progression in a subtype- and microanatomical niche-dependent manner, thereby laying a framework for the discovery of targetable metabolic vulnerabilities in glioblastoma.

课题合作 · 扫码加微信
bioinformaticsboy